Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment.
Fiche publication
Date publication
avril 2024
Journal
United European gastroenterology journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Caron B, Habert A, Bonsack O, Camara H, Jeanbert E, Parigi TL, Netter P, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Many patients with inflammatory bowel disease (IBD) have signs or symptoms of active disease despite multiple treatment attempts. This emerging concept is defined as difficult-to-treat IBD.
Mots clés
Crohn's disease, inflammatory bowel disease, risankizumab, ulcerative colitis, ustekinumab, vedolizumab
Référence
United European Gastroenterol J. 2024 04 9;: